Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Published:2018-12 Issue:12 Volume:19 Page:1668-1679
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Platzbecker Uwe,Middeke Jan Moritz,Sockel Katja,Herbst Regina,Wolf Dominik,Baldus Claudia D,Oelschlägel Uta,Mütherig Anke,Fransecky Lars,Noppeney Richard,Bug Gesine,Götze Katharina S,Krämer Alwin,Bochtler Tilmann,Stelljes Matthias,Groth Christoph,Schubert Antje,Mende Marika,Stölzel Friedrich,Borkmann Christine,Kubasch Anne Sophie,von Bonin Malte,Serve Hubert,Hänel Mathias,Dührsen Ulrich,Schetelig Johannes,Röllig Christoph,Kramer Michael,Ehninger Gerhard,Bornhäuser Martin,Thiede Christian

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel;De Witte;Blood,2017

2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Döhner;Blood,2017

3. Reduced mortality after allogeneic hematopoietic cell transplantation;Gooley;N Engl J Med,2010

4. How I treat refractory acute GVHD;Deeg;Blood,2007

5. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia;Buccisano;Blood,2012

Cited by 273 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hybrid allogeneic bone marrow transplant rescue approach after acute myelogenous leukaemia relapse in a high‐risk patient;British Journal of Haematology;2024-09-05

2. Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study;Frontiers in Immunology;2024-08-26

3. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?;Expert Review of Hematology;2024-07-21

4. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation;Blood;2024-07-18

5. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study;Leukemia;2024-07-17